AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06448156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac arrest and sudden death
Description: Selection of cases with a secondary diagnosis containing the diagnostic keywords cardiac arrest and sudden death.cardiac arrest and sudden death.The incidence rate is then calculated
Study NCT06025721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Risk Homeless Support
Description: There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve cardiovascular health behaviors. The coach will encourage a focus on smoking>medication>sleep>physical activity>healthy eating to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief cardiovascular health education as needed in participants' preferred format (handout, video, audio, etc.).
Study NCT06292481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brunnstorm movement therapy
Description: this group received Brunnstorm Movement therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
Study NCT06332430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN2109
Description: CAN2109 IT injection (once every 3 weeks)
Study NCT05353647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
Description: A single infusion of autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
Study NCT05919810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Oral probiotic
Study NCT05919810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral herbal powder supplement
Description: oral herbal powder
Study NCT06359587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laboratory test overuse (LTO) Bundle
Description: Key Components of the LTO Bundle:~Educational materials, including an online module, clinical decision support tool, provision of lab utilization (Audit and Feedback) reports for healthcare providers.~Patient engagement tools, such as videos and educational infographics. System level implementation tools adapted to the local context, including EMR-based tools and order set changes, etc.
Study NCT06389084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents Together parenting course
Description: parenting course and coaching calls
Study NCT05884320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Given by IV (vein)
Study NCT04906148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advertisement content (explicit vs. implicit)
Description: Participants will be randomly assigned to view an advertisement with either implicit or explicit harm messaging content
Study NCT04906148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advertisement content (true vs. misleading)
Description: Participants will be randomly assigned to view an advertisement with either true or misleading messaging content
Study NCT06243913 — intervention group
Intervention type: PROCEDURE
Intervention: IUI with vitrified sperm from donor:
Description: After signing the informed consent, the clinic's Matching team will assign a donor semen straw based on phenotypic characteristics, blood group, and genetic compatibility (if applicable), with the female partner.~On the day of the Intrauterine Insemination (IUI), the laboratory team will thaw the assigned donor semen straw and post-thaw sperm parameters will be analyzed, including the total number of sperm with progressive motility. Subsequently, the IUI will be performed following the standard protocol.
Study NCT06136728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine 10 MG [Ampyra]
Description: Dalfampridine (10 mg) every 12 hours for 6 weeks.
Study NCT06136728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy (motor relearning for mobility and balance) one-on-one twice per week for 6 weeks.
Study NCT06136728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine plus physical therapy
Description: Dalfampridine (10 mg) every 12 hours for 6 weeks while simultaneously receiving physical therapy (motor relearning for mobility and balance) one-on-one twice per week.
Study NCT04939038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularization
Description: Depending on the condition of the patients, patients will have either endovascular or surgical revascularization
Study NCT04939038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound care
Description: Standard wound care according to guidelines
Study NCT04939038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard wound care
Description: Standard wound care according to guidelines
Study NCT04799288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Teriflunomide 14mg will be administered orally as 1 tablet once daily during the 9-month treatment phase of the study.
Study NCT05439252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Snacking
Description: Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are sit-to-stand from a chair, seated overhead arm raises, march on the spot, seated arm raises and shoulder touches, and seated calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.
Study NCT05954741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor rehabilitation alone
Description: Participants will undergo motor training consisting of a walking session (20 minutes), balance exercises, postural control exercises, proprioceptive exercises, joint mobilization exercises, and muscle strengthening exercises for a total of 25 minutes. A muscle relaxation session will follow (45 minutes).
Study NCT05954741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor rehabilitation and Cognitive rehabilitation (paper-based)
Description: Group 2 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a standard cognitive intervention, with the execution of cognitive exercises in the domains of attention, memory, executive function, visuo-spatial abilities, space-time orientation, by paper-pencil support (45 minutes per day).
Study NCT05954741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor rehabilitation and cognitive rehabilitation (digital-based)
Description: Group 3 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a digital cognitive intervention, with the execution of cognitive exercises on attention, memory, executive functions, visual-spatial ability, space-time orientation, employing device support (tablet) with interactive exercises presented by specific software (VRRS Home tablet Khymeia Srl) (45 minutes).
Study NCT06371300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Red LLLT
Description: Mask with LEDs emitting at wavelengths of 633nm to facial and eyelids region with their eyes closed
Study NCT06371300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red LLLT
Description: Mask with LEDs emitting at wavelengths of 633nm to facial and eyelids region with their eyes closed
Study NCT06371300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue LLLT
Description: Mask with LEDs emitting at wavelengths of 428nm to facial and eyelid regions with their eyes closed
Study NCT06371300 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Red LLLT
Description: Mask with LEDs emitting at wavelengths of 633nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
Study NCT06371300 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Blue LLLT
Description: Mask with LEDs emitting at wavelengths of 428nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
Study NCT06605703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion-Naltrexone-Metformin
Description: Bupropion-Naltrexone-Metformin
Study NCT06602193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122 225 mg
Description: Administered as specified in the treatment arm
Study NCT06602193 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BIIB122-Matching Placebo
Description: Administered as specified in the treatment arm
Study NCT06292481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Brunnstorm Movement therapy and low level laser therapy
Description: this group received Combined Brunnstorm Movement therapy and low level laser therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
Study NCT05679024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 2.5 milligram Oral Tablet
Description: Oral Tablet
Study NCT05365308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical supports
Description: Quality improvement tools for iron deficiency anemia that include computer-assisted identification, an EHR registry, facilitated GI referral, an EHR tool for documentation, and physician education
Study NCT04853563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: High PEEP targeted to 10 cmH2O to be maintained during the period of mechanical ventilation compared with low PEEP maintaining 3-5 cmH2O
Study NCT04853563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP
Description: High PEEP targeted to 10 cmH2O to be maintained during the period of mechanical ventilation compared with low PEEP maintaining 3-5 cmH2O
Study NCT05822089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
Study NCT05667519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional guidance of lead implantation by transesophageal echocardiography
Description: Transesophageal echocardiography guidance of lead implantation targeting a stable lead position in a tricuspid valve commissure (preferentially postero-septal) and an apical ventricular lead position
Study NCT06586606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1708
Description: Oral administration
Study NCT06586606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral administration
Study NCT05822089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
Study NCT05822089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
Study NCT05822089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
Study NCT05822089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
Study NCT05822089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed
Study NCT05822089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (IC-8 Apthera) in one eye if irregular astigmatism is observed
Study NCT05005026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR Game 1
Description: Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart.
Study NCT05005026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR Game 2
Description: Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart.
Study NCT04523168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Neovasc Reducer™ System
Description: A stainless-steel mesh pre-mounted on a customized hourglass shaped balloon catheter, is designed to create a focal narrowing in the lumen of the CS to generate a pressure gradient across it.
Study NCT06558617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARC-F Questionnaire
Description: The SARC-F scale consists of five components: strength, walking assistance, rising from a chair, stair climbing, and falls. These elements were selected to reflect changes in health status related to the effects of sarcopenia. Scores on the SARC-F scale range from 0 to 10, composed of five domains, assesses strength, walking assistance, raising from a chair, stair climbing and falls. Each domain score ranges from 0-2. A SARC-F score of ≥4 was considered abnormal. The Thai-version SARC-F questionnaire has been validated in Thai older adults.
Study NCT06558617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Calf Circumference Measurement
Description: Calf circumference was measured using a nonelastic tape measure while the participant was standing with relaxed legs. The tape was placed snugly and flat around the widest part of the calf, parallel to the floor. According to the AWGS 2019 criteria, calf circumferences were considered abnormal if they were less than 34 cm for males and less than 33 cm for females.
Study NCT06558617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARC-CalF Questionnaire
Description: This questionnaire integrates the SARC-F and calf circumference as a trigger for case finding. If the calf circumference is below the cut-off value, 10 points are added to the SARC-F score for evaluation. The SARC-CalF score ranges from 0 to 20, with a score of ≥11 considered abnormal for sarcopenia screening.
Study NCT06270225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg
Description: Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
Study NCT06270225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Description: Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
Study NCT06270225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 mg
Description: Subjects will receive 0.5mg/d Colchicine for 12 weeks.
Study NCT04853329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO107
Description: CD20-CD47 Bispecific Fusion Protein
Study NCT06685250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy
Study NCT06683703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone combined with Bevacizumab
Description: The initial dose was Utidelone 30mg/m2/d,D1-D5,Q3W+ Bevacizumab 15mg/kg/Q3w. If dose adjustment was required due to DLT events, Utidelone was reduced by up to one dose (to 25mg/m2/d), while the dose of Bevacizumab remained unchanged (15mg/kg).
Study NCT06683703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: Utidelone injection, 30mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle
Study NCT06411444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grape Design Nasal Stent
Description: Grape Design Nasal Stent
Study NCT06411444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Grape Design Nasal Stent
Description: Grape Design Nasal Stent
Study NCT05859815 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physical Therapy
Description: As part of their normal care, participants will receive any combination of the following interventions to address their specific needs identified during the initial evaluation: cervical spine repeated movements (active range of motion), cervical spine stabilization exercise, aerobic exercise, motor control training, oculomotor/vestibular rehabilitation, stretching, soft-tissue mobilization, joint mobilization, and postural re-education activities.
Study NCT06134414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization
Study NCT05561621 — intervention group
Intervention type: OTHER
Intervention: Voice analysis
Description: Voice analysis
Study NCT05619692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: Softgel lipid capsules.
Study NCT05619692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAGE-718-matching Placebo
Description: Softgel lipid capsules.
Study NCT06120803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Description: Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy.
Study NCT05024682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional pulsed radiofrequency
Description: After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 120 seconds pulse mode which consisted of four cycles (8 minutes)
Study NCT05024682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse dosed pulsed radiofrequency
Description: After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 240 seconds pulse dose mode which consisted of two cycles (8 minutes).
Study NCT05262491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion
Study NCT04830462 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin 300 Mg Oral Capsule
Description: Rifampicin 600 mg orally once daily for 4 months
Study NCT04830462 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isoniazid 300 Mg ORAL TABLET
Description: Isoniazid 300 mg daily for 6 months
Study NCT05266313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oncosexology program
Description: Thematic workshops throughout the year
Study NCT06338826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI
Description: The study will include patients under current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from~* NNRTI = efavirenz, rilpivirine, etravirine, doravirine~* PI/r = atazanavir/r ou darunavir/r~* INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir